web analytics
November 28, 2015 / 16 Kislev, 5776
At a Glance
News & Views
Sponsored Post

Teva’s Parkinson Drug Now Marketed in Japan

JewishPress Logo

Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan.

The rasagiline tablets, which are approved in over 40 countries for the treatment of Parkinson’s disease, gained UK and EU-marketing authorization in 2005 and US FDA approval in 2006.

“It is estimated there are about 150,000-180,000 people diagnosed with Parkinson’s disease in Japan, many of whom are waiting for a new treatment option,” said Nancy Joseph-Ridge, M.D., General Manager of Takeda’s Pharmaceutical Development Division located in Osaka, Japan in a press release on April 27.

“We will continue working on the development in cooperation with Teva so that we can bring this medicine to Japanese patients as quickly as possible,” Joseph-Ridge said.

“This agreement represents Teva’s continued commitment to introducing our innovative medicines to patients in Japan,” added Teva Global R&D president and Chief Scientific Officer, Dr. Michael Hayden.

Teva and Takeda entered an agreement in December 2013 to develop glatiramer acetate for the treatment of multiple sclerosis.

Developed by Teva, rasagiline was initially discovered by two Haifa Technion professors, John Finberg and Moussa Youdim, who were instrumental in the early clinical development of the anti-Parkinson drug.

Parkinson’s disease is a degenerative disorder of the central nervous system, whose symptoms include shaking, rigidity, slowness of movement and difficultly with walking as well as dementia in advanced stages. An estimated seven to 10 million people suffer from the disease across the world according to the Parkinson’s Disease Foundation.

According to Teva’s website, rasagiline is a monoaxmine oxidase B (MAO-B) inhibitor that increases available synaptic dopamine in the brain, which might improve the motor symptoms characteristic of Parkinson’s, slowing the progression of the disease.

“Rasagiline has an established safety and efficacy profile…[it] will be an important product for Japan, where the number of available treatment options for Parkinson’s disease remains limited,” said Dr. Hayden.

About the Author: Anav Silverman is a regular contributor to Tazpit News Agency.

If you don't see your comment after publishing it, refresh the page.

Our comments section is intended for meaningful responses and debates in a civilized manner. We ask that you respect the fact that we are a religious Jewish website and avoid inappropriate language at all cost.

If you promote any foreign religions, gods or messiahs, lies about Israel, anti-Semitism, or advocate violence (except against terrorists), your permission to comment may be revoked.

2 Responses to “Teva’s Parkinson Drug Now Marketed in Japan”

  1. Judith Dowla says:

    TEVA is an excellent pharmaceutical company that offers a considerable amount of funds into research and is on the leading edge in finding the best possible treatment for various diseases and with a focus as well on receptors involving the nerves that become disturbed via a variety of causes. The goal is to do what is best to help the patient overcome and manage the disturbances that can make life very uncomfortable. Keep up the good work TEVA.

Comments are closed.

Current Top Story
Ambulances evacuate wounded soldiers at the scene where a Palestinian Arab driver rammed his car into Israeli soldiers near Beit Ummar, on November 27, 2015.
On This Violent ‘Day of Rage,’ a/k/a Friday, Closure Imposed on PA Villages

Printed from: http://www.jewishpress.com/news/breaking-news/tevas-parkinson-drug-now-marketed-in-japan/2014/05/29/

Scan this QR code to visit this page online: